literature

HIV mutation literature information.

Tipranavir: a new protease inhibitor for the treatment of antiretroviral-experienced HIV-infected patients.

PMID: 17425479 2007 Expert opinion on pharmacotherapy

Abstract: The TPV mutation score includes L10V, I13V, K20M/R/V, L33F, E35G, M36I, K43T, M46L, I47V, I54A/M/V, Q58E, H69K, T74P, V82L/T, N83D and I84V.

Polymorphisms and resistance mutations in the protease and reverse transcriptase genes of HIV-1 F subtype Romanian strains.

PMID: 16762582 2007 International journal of infectious diseases

Abstract: The most frequent mutation was M36I (29 of 29 strains), followed by L63T, K20R, and L10V.

Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.

PMID: 16875739 2007 The Journal of infection

Abstract: Two patterns of mutations in the protease were identified: (M46I/L, I54V, V82A/T/F) was associated to the A431V and (K20I/R/M, L89M/I) to the S373Q and L449P.

A novel substrate-based HIV-1 protease inhibitor drug resistance mechanism.

PMID: 17227139 2007 PLoS medicine

Method: In addition, the model was also adjusted on use of nelfinavir at baseline and on the number of PI mutations (L10IRVF, K20RM, M36I, A71VT, G73SA, V82AFTS, L90M) found to be associated with the virological response in univariate analyses in this subset of patients.

Genotypic resistance mutations to antiretroviral drugs in treatment-naive HIV/AIDS patients living in Liaoning Province, China: baseline prevalence and subtype-specific difference.

PMID: 17411368 2007 AIDS research and human retroviruses

Abstract: The frequencies of minor mutations to protease inhibitors (PI) were I93L (71.4%), L63P (62.6%), V77I (62.6%), M36I/V (33.0%), A71T/V (22.0%), K20R (6.6%), G16E (6.6%), and L10I (5.5%).

Sequential emergence and clinical implications of viral mutants with K70E and K65R mutation in reverse transcriptase during prolonged tenofovir monotherapy in rhesus macaques with chronic RT-SHIV infection.

PMID: 17417971 2007 Retrovirology

Result: The mutations most commonly observed (sometimes transiently) after the detection of K65R included K20R (3 animals), M41L (3 animals), S68G/K/N (12 animals), K70H/N/T/Q (9 animals), W88S (6 animals), Y115F (9 animals), F116W (6 animals), V118I (3 animals), I178M (6 animals), L214F (11 animals), and K219Q/R/E/N/D/H/G (7 animals) (table 1).

Table: K20R

HIV-1 subtype B protease and reverse transcriptase amino acid covariation.

PMID: 17500586 2007 PLoS computational biology

Method: PI-selected mutations included L10I/V/F/R, V11I, K20R/M/I/T, L23I, L24I, D30N, V32I, L33F/I, E34Q, E35G, M36I/V, K43T, M46I/L/V, G48V/M, I50V/L, F53L, I54V/M/L/T/A/S, K55R, Q58E, L63P,

Polymorphisms and drug resistance analysis of HIV-1 CRF01_AE strains circulating in Fujian Province, China.

PMID: 17619115 2007 Archives of virology

Abstract: The proportion of substitutions L63P, A71T/V, V77I and I93L in subtype B' sequences was considerably higher than in CRF01_AE viruses, while the proportion of L10I, M36I and K20R/I substitutions in subtype B' sequences was relatively lower than in CRF01_AE strains.

Predictive factors for response to a boosted dual HIV-protease inhibitor therapy with saquinavir and lopinavir in extensively pre-treated patients.

PMID: 18240863 2007 Antiviral therapy

Abstract: RESULTS: The analyses detected correlations between the primary outcome parameter and several factors: baseline CD4+ T-cell count (P = 0.001); absence of mutations at V82T/A/F/I/S plus 154M/V/L (P = 0.002) or K20M/R (P = 0.010); and lopinavir C(min)GIQ(arch) (P = 0.046).

[Background study of HIV-1 drug resistant mutations in treatment-naive patients in liaoning province].

PMID: 17121220 2006 Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae

Abstract: Minor resistance mutation rate to protease inhibitors was 100%, including types of L63P (60.4%), V77I (60.4%), M36I/V (31.9%), A71V/T (22.0%), L10I (8.8%), and K20R (6.6%).

Browser Board

Co-occurred Entities

Filtrator